TP53 Mutations Promote Immunogenic Activity in Breast Cancer.
Zhixian LiuZehang JiangYingsheng GaoLirui WangCai ChenXiao-Sheng WangPublished in: Journal of oncology (2019)
TP53 mutations may promote immunogenic activity in BC, suggesting that the TP53 mutation status could be a useful biomarker for stratifying BC patients responsive to immunotherapy.